Publication

2025

Original Articles

• "Prognostic significance of body mass index in patients with metastatic renal cell carcinoma receiving first-line therapies"
  Keigo Sato, Kosuke Takemura (joint first author), Ryosuke Oki, Tetsuya Urasaki, Yusuke Yoneoka, Ryo Fujiwara, Yosuke Yasuda, Tomohiko Oguchi, Noboru Numao, Shinya Yamamoto, Junji Yonese, Haruki Kume, Takeshi Yuasa.
  Urol Oncol. 43, 4, 269.e1-269.e6. (2025).

  • DOI: 10.1016/j.urolonc.2024.12.265.

Abstract Presentations

• "Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)"
  Kosuke Takemura, Jeffrey Graham, David Maj, Martin Zarba, J Connor Wells, Razane El Hajj Chehade, Marc Eid, Eddy Saad, Renee Maria Saliby, Jae-Lyun Lee, Frede Donskov, Benoit Beuselinck, Evon Jude, Rana R McKay, Naveen S Basappa, Sumanta K Pal, Camillo Porta, Neeraj Agarwal, Toni K Choueiri, Daniel Y C Heng.
  J Clin Oncol. 43, 5 Suppl, 494 (2025).

  • DOI: 10.1200/JCO.2025.43.5_suppl.494

Review Articles

• "Rethinking evidence standards for men with metastatic prostate cancer in the post-androgen receptor pathway inhibitor setting: new insights from CONTACT-02"
  Kosuke Takemura, Takeshi Yuasa.
  Transl Androl Urol. 14, 11, 3457-3459 (2025).

  • DOI: 10.21037/tau-2025-701
• "Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review"
  Ryosuke Oki, Kosuke Takemura (corresponding author), Tetsuya Urasaki, Ryo Fujiwara, Noboru Numao, Junji Yonese, Yuji Miura, Takeshi Yuasa
  Expert Rev Anticancer Ther. 25, 6, 643-655 (2025).

  • DOI: 10.1080/14737140.2025.2491647.
• "Evaluating the genetic landscape of prostate cancer: new insights from BRCA1/2, ATM and CDK12 mutations"
  Fumihiko Urabe, Kosuke Takemura
  BMJ Oncol. 4, 1, e000717 (2025).

  • DOI: 10.1136/bmjonc-2024-000717.